The findings, published in the March issue of Gastroenterology, revealed no significant difference in positive predictive value between average risk patients who received a guaiac fecal occult blood test in the first round and those who received a fecal immunochemical test in the first round.
Researchers said, however, that “no large difficulties are to be expected should a switch from a guaiac-based program to a FIT-based program be desired in screening programs currently using guaiac tests.”
Related Articles on GI and Endoscopy:
Kentucky Public-Private Partnership to Fund Colon Cancer Screenings for the Uninsured
Regulators Work to Limit Weight Loss Pill Qnexa, Citing Safety Concerns
Dr. Joseph Brasco: 5 Points on Fecal Microbiota Transplant in an ASC
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
